Yazılar

Apple Backs Google’s Billion-Dollar Search Payments in Court Battle

/in /tarafından

Apple Seeks Role in Google’s Antitrust Case to Defend Revenue-Sharing Deals

Apple has requested to participate in Google’s upcoming U.S. antitrust trial concerning online search dominance. The tech giant aims to protect the lucrative revenue-sharing agreements that provide it with billions of dollars annually for making Google the default search engine on its Safari browser. Apple argued that it cannot depend on Google to adequately defend these arrangements, which are crucial to its business.

In court documents filed in Washington on Monday, Apple clarified that it has no plans to develop its own search engine, even if its agreements with Google were to end. In 2022 alone, Apple reportedly earned an estimated $20 billion (roughly Rs. 1,70,544 crore) from its partnership with Google, highlighting the financial significance of the deal.

Apple has expressed its intent to call witnesses to testify during the trial scheduled for April. These witnesses are expected to provide insight into the nature of the agreements and their role in the digital ecosystem. Apple’s involvement reflects its vested interest in maintaining the status quo and shielding its partnership with Google from antitrust repercussions.

Meanwhile, prosecutors plan to argue that Google’s dominance in online search stifles competition and requires drastic measures. Their proposed remedies include compelling Google to divest key assets, such as its Chrome web browser and potentially its Android operating system, to foster a more competitive landscape. The case could have far-reaching implications for the tech industry and its reliance on revenue-sharing arrangements.

Nvidia Completes $700 Million Acquisition of Run:ai After Regulatory Scrutiny

/in /tarafından

Nvidia has successfully completed its $700 million acquisition of Israeli AI startup Run:ai, following regulatory scrutiny from antitrust authorities. The European Commission granted unconditional approval for the deal earlier in December, after initially flagging concerns about potential competition issues. The acquisition, which had been under investigation due to Nvidia’s dominant position in the graphics processing unit (GPU) market, was cleared after the Commission determined it would not hinder competition. The U.S. Department of Justice is also reviewing the deal on antitrust grounds. Run:ai, known for its AI infrastructure optimization tools, announced plans to make its software open-source, extending its compatibility beyond Nvidia’s GPUs to support the broader AI ecosystem.

 

Regulatory Conditions Cleared for Novo Holdings’ $16.5 Billion Catalent Acquisition

/in /tarafından

Novo Holdings announced on Saturday that all regulatory conditions for its $16.5 billion acquisition of U.S. contract drug manufacturer Catalent have been fulfilled. The companies anticipate completing the transaction in the coming days.

The acquisition, initially agreed upon in February, is part of Novo Holdings’ strategy to increase production of the blockbuster weight-loss drug Wegovy, developed by its affiliate Novo Nordisk. As part of the agreement, Novo Holdings will sell three of Catalent’s factories located in Italy, Belgium, and the United States to Novo Nordisk for $11 billion. These facilities specialize in filling injection pens under sterile conditions.

Novo Holdings is the controlling shareholder of Novo Nordisk, the Danish pharmaceutical giant behind the popular GLP-1 injectable drug Wegovy. Novo Nordisk stated that while the acquisition aligns with its strategic goals, it is expected to have a mid single-digit negative impact on operating profit growth in 2025. Consequently, the company does not plan to initiate a share buyback program for the year.

Regulatory and Antitrust Scrutiny

The deal has faced close regulatory scrutiny. Earlier in December, the European Commission granted EU antitrust approval, stating that the merger posed no competition concerns within the European Economic Area (EEA).

In the United States, the acquisition drew criticism from consumer groups, labor unions, and policymakers. U.S. Senator Elizabeth Warren urged the Federal Trade Commission (FTC) to scrutinize the deal, citing potential concerns. The FTC had requested additional information on the acquisition in May, but no further updates have been issued.

Strategic Implications

The transaction underscores Novo Holdings’ commitment to expanding its role in the manufacturing and distribution of high-demand pharmaceuticals. By integrating Catalent’s production capabilities, Novo Holdings aims to meet the growing demand for weight-loss treatments while maintaining compliance with global competition regulations.